News & Publications
- External News
CrossBridge Bio Awarded $15 Million CPRIT Grant to Advance CBB-120, Its Lead Dual-Payload ADC Targeting TROP-2, Into the Clinic
CrossBridge Bio, a biotechnology company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer, more durable responses for patients, including those resistant to approved ADC therapies, today announced it has been awarded a $15 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The award will support completion of IND-enabling activities and advancement of CBB-120, the company’s lead TROP-2 targeted TOP1i/ATRi dual-payload ADC, into first-in-human studies.
- External News
CrossBridge Bio Wins “Best Drug Developer” at 2025 World ADC Awards
HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biopharmaceutical company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer more durable responses in patients, including those resistant to approved ADC therapies, today announced that it has been named the Winner of “Best Drug Developer” at the 2025 World ADC Awards.
- Publication
CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC Therapies
CrossBridge Bio has secured $10 million in seed financing, led by TMC Venture Fund and CE-Ventures, to advance its next-generation dual-payload antibody-drug conjugates (ADCs) for targeted cancer therapy. This funding will accelerate development of CBB-120, a promising TROP-2 ADC for solid tumors, and support CrossBridge Bio’s groundbreaking platform that enhances stability and payload synergy. With experienced investors and strategic board appointments, CrossBridge Bio is set to redefine cancer treatment with precision-targeted therapies.
- Publication
Redefining Cancer Treatment: CrossBridge Bio’s Breakthrough in Stable, Multi-Loaded ADCs
CrossBridge Bio is pioneering the next generation of antibody-drug conjugates (ADCs) with a focus on stability and multi-payload design. Leveraging cutting-edge technology from UTHealth Houston, the company is developing dual-payload ADCs that improve targeting and minimize side effects, advancing treatments for cancers with unmet needs. With support from CPRIT and industry leaders, CrossBridge Bio aims to deliver breakthrough cancer therapies, beginning with its lead candidate, CBB-120, for TROP-2-positive tumors.
- Internal News
CrossBridge Bio, Inc. Receives $2.6M in Non-Dilutive Funding from CPRIT to Advance, CBB-120, a Next-Generation Dual-Payload Antibody-Drug Conjugate for the Treatment of TROP-2+ Solid Tumors
CrossBridge Bio, Inc. proudly announces the receipt of a substantial competitive non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant marks a significant milestone in CrossBridge's mission to propel its innovative dual-payload ADC platform and potential best-in-class TROP2 program, CBB-120, to IND-enabling studies.
- Publication
An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody-drug conjugates.
Valine–citrulline is a protease-cleavable linker commonly used in many drug delivery systems, including antibody–drug conjugates (ADC) for cancer therapy. However, its suboptimal in vivo stability can cause various adverse effects such as neutropenia and hepato- toxicity, leading to dose delays or treatment discontinuation. Here, we report that glutamic acid–glycine–citrulline (EGCit) linkers have the potential to solve this clinical issue without compromising the ability of traceless drug release and ADC therapeutic efficacy.
Events
The American Association for Cancer Research will take place on the 5th - 10th April 2024 at the San Diego Convention Center.
- April 5, 2024
- — April 10, 2024
The ASCO Annual Meeting will take place from May 31 - June 4, 2024.
- May 31, 2024
- — June 4, 2024